Skip to content
Options Trading Report

Options Trading Report

Primary Menu
  • Home
  • Business
  • Domestic
  • Economy
  • Money
  • Top News
  • Newsletters
  • Home
  • 2025
  • October
  • AI startup valuations raise bubble fears as funding surges
  • Newsletters

AI startup valuations raise bubble fears as funding surges

Editor October 3, 2025
NatGold: The Evolution of Money
Options Trading Report Logo

🔥 This simple trade happens 3-5x’s a week, Options expert shares his strategy. [sponsor]

‘NextGen’ US air traffic reform effort faces delays, rising costs

WASHINGTON (Reuters) -The Federal Aviation Administration’s $15 billion project to overhaul air traffic control has faced numerous delays, cost overruns and is less ambitious than what was envisioned more than 20 years ago, according to a new report.Through the end of 2024, the FAA has achieved only about 16% …

Read More »
NatGold: The Evolution of Money [sponsor]
Bitcoin proved the world was ready to escape fiat-but it came with flaws: volatility, no backing, and massive energy waste. NatGold fixes that. It’s a digitally mined token backed by verified gold still in the ground-merging Bitcoin’s scarcity with the trust of gold. No extraction, no storage, no pollution. Just real gold, digitally secured and tradeable. Built by former SEC advisors and global mining leaders, NatGold is opening reservations now. Only 100,000 token reservations will be accepted-and the first 10,000 purchased on Tokenization Day receive a guaranteed 10% discount to gold’s Baseline Intrinsic Value. Reserve your NatGold Tokens today before the discount window closes forever.

BlackRock’s infrastructure play gets a boost as Minnesota approves buyout

The outcome of a meeting of the Minnesota Public Utility Commission, which was webcast, may reassure investors that BlackRock will be able to address regulatory and antitrust concerns as its Global Infrastructure Partners unit, which it bought last year, presses to buy other utilities.(Reporting by Ross Kerbe …

Read More »
Is Nvidia about to Trigger Another 150X Opportunity? [sponsor]
Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic processing units. Legendary investor Louis Navellier believes this new invention could be even more revolutionary and mint a new wave of millionaires. Click here to get the details.

OPEC set for another oil hike as Saudi and Russia debate size, sources say

LONDON/MOSCOW (Reuters) -Eight OPEC countries are likely to further raise oil output on Sunday with the group’s leader Saudi Arabia pushing for a large increase to regain market share and Russia suggesting a more modest rise, four people with knowledge of OPEC talks said.Russia and Saudi Arabia, the tw …

Read More »
Did ChatGPT Just Kill Google? [sponsor]
Newsweek says ChatGPT may have ended Google. “Give me a break!” says famed ex-hedge fund manager Whitney Tilson who put his kids’ college savings in Google in 2018. (It’s up 369% since then.) Whitney believes that Google’s latest move will silence all skeptics forever. Click here for his new prediction.

AI startup valuations raise bubble fears as funding surges

SINGAPORE (Reuters) -Artificial intelligence startups are attracting record sums of venture capital, but some of the world’s largest investors warned that early-stage valuations are starting to look frothy, senior investment executives said on Friday.”There’s a little bit of a hype bubble going on in the earl …

Read More »
“The America you knew is dying in front of you” [sponsor]
That’s the urgent warning the former $200 million hedge fund firm manager who predicted 2008 and 2020 just issued. He says if you’re over 50, there’s one urgent move you need to make to survive… or risk getting left behind. The rules are changing: Here’s your financial lifeline.

US FDA launches pilot program to fast-track review of domestically made generic drugs

The program is designed to encourage companies to invest in domestic drug production and research by offering faster approvals for products made with U.S.-sourced ingredients and tested within the country.Earlier this week, the FDA held a public meeting to discuss its broader efforts to support U.S. pharmaceu …

Read More »
FDA Approval Could Send this Stock Soaring [sponsor]
Whenever the FDA approves a new drug… Timely investors could see 300-400% returns… ChemoCentryx soared 281% in the year after it won FDA approval… Immunogen jumped 449% in the two years after it won FDA approval… Even Krystal Biotech rose 242% when it looked like it would win FDA approval, which it did. Here’s the next stock we think has a good chance of winning FDA approval.

You Might Also Like

Strange Options Secret (NOT Day Trading!) [sponsor]

Trading Options in 2025 [sponsor]

Check out this simple options system [sponsor]


Be sure that you receive future email from Options Trading Report – please whitelist our email address with your email provider..

DISCLAIMER
This message is for informational purposes only and does not constitute investment advice or an offer to buy or sell securities. Always conduct your own due diligence. The views expressed are those of the author and do not necessarily reflect those of the sender. This is a paid advertisement. Sponsored emails like this may include promotional content from third-party advertisers. Options Trading Report is owned and operated by BMF Financial, LLC. We are not investment advisors. Your capital is at risk.

IMPORTANT NOTICE AND DISCLAIMER
BMF FINANCIAL, LLC(“BMF”), the owner of this website (the “Website”), cannot guarantee the accuracy or completeness of the information contained in any article, email, newsletter, or other publication posted on or viewed in connection with this website (the “Publications”). The author or authors of those Publications are solely responsible for their contents. BMF has not done any research or due diligence into the markets, industries, or companies which may appear or be mentioned in the Publications. BMF will NOT be liable for any loss or damage caused by a reader’s reliance on information posted on the Website or contained in the Publications.

FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE.
This Website and the Publications are for educational and informational purposes only. This Website and the Publications do not purport to be a complete analysis of any company’s financial position. This Website, the Publications or any statements made in the Publications are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual.This Website or the statements made in the Publications should NOT be relied upon for purposes of transacting in any securities posted on the Website or mentioned in the Publications, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security posted on this Website or mentioned in any Publications.b>

SUBSTANTIAL RISK IN INVESTMENT.
Any individual who chooses to invest in any securities including those mentioned in the Publications should do so with caution.Investing or transacting in securities involves substantial risk; you may lose some, all, or possibly more than your original investment.Readers bear responsibility for their own investment research and decisions and should review all investment decisions with a licensed or registered investment professional.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER
Neither BMF nor any of its respective owners or employees are registered or licensed as a securities broker-dealer, broker, an investment advisor, or an investment advisor representative with the U.S. Securities and Exchange Commission (SEC), any state securities regulatory authority, or any self-regulatory organization.


For full policies, see our:  Disclaimer | Privacy | Terms

Options Trading Report
203 N La Salle Street, Suite 2100 | Chicago, IL 60601

unsubscribe

About the Author

Editor

Administrator

Visit Website View All Posts

Post navigation

Previous: US FDA launches pilot program to fast-track review of domestically made generic drugs
Next: OpenAI to boost content owners’ control for Sora AI video app, plans monetization

Related Stories

  • Newsletters

Critical Metals shares soar after Reuters report says Washington eyeing stake

Editor October 6, 2025
  • Newsletters

Elon Musk’s $1 trillion pay plan faces pushback from investors, state officials

Editor October 5, 2025
  • Newsletters

Exclusive-Trump administration eyes stake in company developing Greenland rare earths mine

Editor October 4, 2025

Live Market Pulse

The charting technology is provided by TradingView. Learn how to use theTradingView Stock Screener.

Want More Market News?
Add your email address below to get up to date market news and more!
By submitting the form you agree to the Privacy Policy of Options Trading Report and agree to receive our email updates and special offers. As a bonus, you will also get a free subscription to MTA Trade of the Day, Privacy Policy. You will receive special offers and advertisements from Options Trading Report and MTA Trade of the Day and our affiliates. You may unsubscribe at any time.

Search

Recent Posts

  • Critical Metals shares soar after Reuters report says Washington eyeing stake
  • Oil rises after OPEC+ hikes output less than expected
  • Critical Metals shares soar after Reuters report says Washington eyeing stake
  • AstraZeneca signs up to $555 million AI deal with Algen to develop therapies
  • AI venture funding continued to surge in third quarter, data shows

Categories

  • Business
  • Market News
  • Newsletters
  • Options
  • Reflections
  • Top News

You may have missed

  • Newsletters

Critical Metals shares soar after Reuters report says Washington eyeing stake

Editor October 6, 2025
2025-10-05T221541Z_1_LYNXNPEL940EK_RTROPTP_4_USA-OIL-PERMIAN
  • Market News

Oil rises after OPEC+ hikes output less than expected

Editor October 6, 2025
2025-10-06T095716Z_1_LYNXNPEL950E0_RTROPTP_4_DENMARK-USA-GREENLAND
  • Market News

Critical Metals shares soar after Reuters report says Washington eyeing stake

Editor October 6, 2025
2025-10-06T133040Z_4_LYNXNPEL950I9_RTROPTP_4_ASTRAZENECA-GENE-THERAPY-ALGEN
  • Market News

AstraZeneca signs up to $555 million AI deal with Algen to develop therapies

Editor October 6, 2025
  • Home
  • Terms of Service
  • Privacy Policy
  • Disclaimer
  • Contact Us
Copyright 2025 © All rights reserved | Options Trading Report | optionstradingreport.com